{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:32:25Z","timestamp":1773797545265,"version":"3.50.1"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laryngorhinootologie"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Immunpathogenese und Genetik Auch beim BS (Beh\u00e7et-Syndrom) spielt die Neutrophilen-\n  (Hyper-)Aktivierung und die daraus hervorgehende NETosis eine wichtige Rolle.<\/jats:p><jats:p>\n            Klinische Befunde Neben den 4 Kardinalsymptomen \u2013 n\u00e4mlich rezidivierende orale Aphthen, genitale Aphthen sowie Haut- und Augenl\u00e4sionen \u2013 bietet das Krankheitsbild zahlreiche weitere Manifestationen, die h\u00e4ufig eine interdisziplin\u00e4re Zusammenarbeit erfordern. Dies gilt neben der Augenbeteiligung, die bei inad\u00e4quater Behandlung immer noch zur Erblindung f\u00fchren kann, insbesondere auch f\u00fcr intestinale und zerebrale Manifestationen sowie f\u00fcr die Gro\u00dfgef\u00e4\u00df-Vaskulitis.<\/jats:p><jats:p>\n            Therapie Eine letzte \u00dcberarbeitung der EULAR-Empfehlungen erfolgte 2018.\u00a0Die Empfehlungen sind mittlerweile als wichtiger Behandlungsleitfaden international etabliert. Die Therapie richtet sich nach der f\u00fchrenden Organbeteiligung. Nachdem 2016 Adalimumab eine Zulassung f\u00fcr die Behandlung der hinteren Augenbeteiligung erhielt, steht mit Apremilast seit 2020 ein weiterer Wirkstoff zur Verf\u00fcgung. Empfohlen wird das Medikament f\u00fcr die Behandlung rezidivierender oraler Aphthen bei erwachsenen Beh\u00e7et-Patienten, die einer systemischen Therapie bed\u00fcrfen. Es besteht dennoch ein weiterer Bedarf an neuen Substanzen.<\/jats:p>","DOI":"10.1055\/a-2249-2116","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T23:53:46Z","timestamp":1707436426000},"page":"352-357","source":"Crossref","is-referenced-by-count":1,"title":["Neues zum Beh\u00e7et-Syndrom"],"prefix":"10.1055","volume":"103","author":[{"given":"Theodoros","family":"Xenitidis","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II (H\u00e4matologie\/Onkologie\/Klinische Immunologie\/Rheumatologie), Vaskulitiszentrum S\u00fcd, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Christoph","family":"Henes","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II (H\u00e4matologie\/Onkologie\/Klinische Immunologie\/Rheumatologie), Vaskulitiszentrum S\u00fcd, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/a-1076-9742","article-title":"Behcet\u2019s Syndrome","volume":"99","author":"T Xenitidis","year":"2020","journal-title":"Laryngorhinootologie"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"G Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.revmed.2013.12.005","article-title":"Epidemiology of Behcet\u2019s disease","volume":"35","author":"A Mahr","year":"2014","journal-title":"Rev Med Interne"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00347-012-2601-4","article-title":"Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data","volume":"109","author":"A Altenburg","year":"2012","journal-title":"Ophthalmologe"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-020-01381-0","article-title":"Reuma.pt\/vasculitis \u2013 the Portuguese vasculitis registry","volume":"15","author":"C Ponte","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/rheumatology\/keaa010","article-title":"Epidemiology, morbidity and mortality in Behcet\u2019s disease: a cohort study using The Health Improvement Network (THIN)","volume":"59","author":"T Thomas","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","article-title":"Behcet\u2019s Disease: An Overview of Etiopathogenesis","volume":"10","author":"P Leccese","year":"2019","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9680","DOI":"10.1074\/jbc.M117.789180","article-title":"The Behcet\u2019s disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing","volume":"292","author":"P Guasp","year":"2017","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.13049","article-title":"Is Behcet\u2019s disease a \u2018class 1-opathy\u2019? The role of HLA-B*51 in the pathogenesis of Behcet\u2019s disease","volume":"191","author":"M Giza","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/cei.13664","article-title":"Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behcet\u2019s syndrome","volume":"206","author":"A Bettiol","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","article-title":"Critical role of neutrophil extracellular traps (NETs) in patients with Behcet\u2019s disease","volume":"78","author":"A Le Joncour","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Behcet\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u2019s D","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Behcet\u2019s syndrome","volume":"14","author":"E Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/14397595.2020.1830504","article-title":"Efficacy and safety of apremilast for 3 months in Behcet\u2019s disease: A prospective observational study","volume":"31","author":"L Hirahara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-Tumor Necrosis Factor alpha versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network","volume":"129","author":"M Leclercq","year":"2022","journal-title":"Ophthalmology"},{"issue":"05","key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Behcet\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"132","author":"B Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219810","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Behcet\u2019s syndrome\u2019","author":"J Zou","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Laryngo-Rhino-Otologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2249-2116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:51:19Z","timestamp":1730825479000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2249-2116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":17,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2249-2116","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0935-8943","1438-8685"],"issn-type":[{"value":"0935-8943","type":"print"},{"value":"1438-8685","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}